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Abstract  22 
Background: Thyroid eye disease (TED) causes a number of esthetic and visual problems and 23 
its treatment requires close clinical assessment, often for several years.  There is evidence to 24 
suggest that clinical factors are poor indicators of patient-reported outcomes after 25 
treatments that aim to improve appearance, vision, or both.  Psychosocial factors can 26 
impact on both adjustment to living with TED and also patieŶts͛ peƌĐeptioŶs of their 27 
improvements after treatment.  There has been growing recognition that it is essential to 28 
evaluate treatment efficacy in terms of psychosocial outcomes but, to date, there has been 29 
no review that has systematically evaluated psychosocial outcomes following a variety of 30 
treatments for TED.   31 
Summary: Fifteen studies were included in the review and 6 were randomized controlled 32 
trials (RCTs).  The studies varied greatly in methodological rigor; whilst major treatments 33 
such as surgery do improve quality of life outcomes, other non-invasive treatments such as 34 
intravenous steroids can have a similar impact and show long-term benefits.  Only 3 studies 35 
reviewed orbital decompressive surgery which showed better psychosocial outcomes than 36 
other types of surgery.   37 
Conclusions: The effect of some treatments remains unclear due to poor methodology and 38 
poor reporting of results. Clinicians need to be aware when planning rehabilitative 39 
treatments such as surgery the influence of psychosocial factors on quality of life outcomes 40 
and the lack of a relationship with clinical factors such as disease severity. 41 
Introduction 42 
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Thyroid eye disease (TED) is an autoimmune disorder with an annual incidence of 16 43 
in 100,000 women and 3 in 100,000 men (1) and it leads to functional deficits that include 44 
dry eyes, double vision, and pain. It can also cause drastic changes in appearance, including 45 
redness and swelling of the eyelids, eyelid retraction, and proptosis.  These visual limitations 46 
and changes in appearance can have a significant impact on a patient͛s psychological 47 
functioning and quality of life.  Patients with TED not only report being unable to carry out 48 
day-to-day activities – such as reading, driving and watching television (2,3) – but also 49 
experience distress in social situations and difficulty maintaining social relationships (4), this 50 
leading to social isolation and an altered sense of social identity (5).  51 
There are a number of treatments for active TED including radiotherapy, systemic 52 
steroids, or a combination of the two, and other drug treatments such as pentoxifylline, 53 
selenium, rituximab and long-acting release octreotide (octreotide-LAR).  Once TED has 54 
stabilized, patients may be offered surgery to improve appearance and vision: this ranges 55 
fƌoŵ ͚ŵiŶoƌ͛ suƌgeƌies, such as eyelid lengthening, to the more intrusive orbital 56 
decompression which involves removal of the bony walls or orbital fat to decrease proptosis 57 
(6).  Although up to four walls of the orbit may be removed during bony decompression 58 
(medial, lateral, superior and inferior), it is extremely uncommon to remove the orbital roof 59 
(7).   60 
The clinical characteristics before treatment, such as disease duration, severity or 61 
activity often do not correlate well with patient reports of how visible they feel their TED is, 62 
and the impact the condition has on their lives (8, 9).  In fact it appears that psychological 63 
processes individual to each patient, such as appearance concerns and a fear of being 64 
negatively evaluated in social situations, might better explain psychosocial adjustment to 65 
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living with TED (10).  It is therefore important to measure psychosocial factors before and 66 
after treatment in order to establish the effects of treatment on well-being.  67 
Patients with TED report concerns about changes in their appearance and poor 68 
psychological adjustment in the period following diagnosis and there is some evidence to 69 
suggest these concerns continue long-term (11).  A number of systematic reviews have been 70 
conducted in order to establish the impact of radiotherapy (12, 13, 14) and orbital 71 
decompression (7) on the quality of life of patients with TED, and radioiodine therapy (RAI) 72 
compared to antithyroid drugs on the progression of eye disease for patients with Gƌaǀes͛ 73 
disease (GD).  One study that reviewed orbital decompression found no evidence for quality 74 
of life improvement after this surgery (7). Similarly, none of the few studies that examined 75 
radiotherapy and quality of life as an outcome measure found any improvement in quality 76 
of life (13-15) and patients with TED have not been distinguished from patients with GD in 77 
terms of quality of life (12). However with the most recent study included in these reviews 78 
having been published in 2005, and with new treatments for TED continually emerging, an 79 
updated evaluation of the current evidence is necessary.  80 
The aim of this review was to determine the psychological impact of treatment for 81 
TED including drug therapy, radiotherapy, and surgical intervention.  82 
 83 
Methods 84 
Inclusion and exclusion criteria 85 
Articles were restricted to those that had recruited adult patients (>16 years) with 86 
TED, and had evaluated the impact of some form of clinical treatment for TED on 87 
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psychosocial well-being. The tool used to measure psychosocial well-being needed to have 88 
been validated and the article needed to be published in a peer-reviewed journal and in 89 
English.  90 
Search for relevant studies 91 
An electronic search was performed using Ovid MEDLINE, EMBASE, PubMed, 92 
PsycINFO, Web of Science, CINAHL, AMED, PsycARTICLES, Cochrane Library, and SCOPUS in 93 
September 2012, using a combination of search terms that included all known medical 94 
teƌŵs foƌ thǇƌoid eǇe disease foƌ eǆaŵple ͞Gƌaǀes͛ ophthalŵopathǇ͟ aŶd ͞dǇsthǇƌoid 95 
oƌďitopathǇ͟, tƌeatŵeŶt Ŷaŵes, aŶd teƌŵs to ƌefleĐt psǇĐhosoĐial adjustŵeŶt, foƌ eǆaŵple 96 
͞ƋualitǇ of life͟ aŶd ͞depƌessioŶ͟.  IŶ additioŶ, eŵail alerts were implemented and 97 
prominent authors found within this search were contacted for details of any further 98 
unpublished related work, or to retrieve elusive articles. The reference lists of all articles 99 
included, and relevant systematic reviews, were also searched for additional studies.  100 
Study selection 101 
Once searches had been conducted, clearly irrelevant titles were removed and, if it 102 
was unclear from the title alone, the abstracts were screened.  All remaining articles were 103 
retrieved in full and screened for eligibility.  The first author (SW) independently selected 104 
the relevant articles and the relevance of these articles was cross-checked by a second 105 
reviewer (HM); any disagreements were resolved in collaboration with a third reviewer (SN) 106 
until consensus was reached.  107 
Quality assessment 108 
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The quality index (QI) developed by Downs & Black (1998) was used to assess the 109 
quality of all included articles (15). The QI is a highly regarded tool (16) that has been widely 110 
used in healthcare research: it consists of 27 items designed for use with both randomized 111 
controlled trials and observational studies and is composed of five subscales reporting, 112 
external and internal validity (both control of bias and confounding) and power.  113 
 114 
Results 115 
Description of the studies 116 
The database searches identified 440 articles and 2 additional citations were 117 
retrieved from other sources, from which a total of 259 titles and abstracts were screened: 118 
71 citations were excluded at this stage (Figure 1).  The full texts of 188 articles were 119 
retrieved and reviewed for inclusion.  After review and consensus, a total of 13 articles 120 
remained with an additional 2 articles that were retrieved from the reference lists, resulting 121 
in 15 articles included in this review.   122 
The characteristics of the included studies are shown in Table 1. The 15 articles 123 
included a total of 1433 patients with TED and most participants were female (1267; 88%) 124 
although not all the studies reported sex distribution.  Six of the studies were randomized 125 
controlled trials (RCTs) and 5 out of 6 were double-blind randomized trials where the 126 
patients and treating clinicians were blind to the type of treatment (17, 18, 19, 20, 21).  One 127 
of the 6 trials was single-blind due to the nature of administering intravenous (IV) steroids 128 
(22). Three out of the 15 studies compared pre-treatment quality of life of TED patients to a 129 
healthy control group (23, 24, 25), 5 included a control group of patients with untreated TED 130 
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(18-21, 26) and the remaining studies had no group for comparison.  In addition, two studies 131 
compared patients with GD without symptoms of eye disease to those with TED (24, 27)  132 
A total of 14 treatments were evaluated (Table 1); methimazole, radioiodine (RAI), 133 
intravenous (IV) glucocorticoids (methylprednisolone), oral glucocorticoids 134 
(methylprednisolone, prednisone, and an unspecified corticosteroid), orbital radiotherapy, a 135 
combination of radiotherapy and oral glucocorticoids, a combination of radiotherapy and IV 136 
glucocorticoids, octreotide-LAR, selenium, pentoxifylline, orbital decompression, eye muscle 137 
surgery, eyelid lengthening, and blepharoplasty.  Three studies reported administering, in 138 
addition to the main drug evaluated in the trial, methimazole and other anti-thyroid drugs in 139 
order to stabilize thyroid function (18, 20, 21): unfortunately the efficacy of the main 140 
treatment in each of these studies might have been overestimated (or underestimated) if 141 
methimazole independently alters eye symptoms and quality of life outcomes. 142 
Quality of life was a primary outcome measure in 7 out of 15 articles (11, 24, 25, 26, 143 
27, 27, 28) and secondary to clinical outcomes in the remaining 8 (18-23, 29, 30).  The SF-144 
36
TM
 was used as an outcome measure in 8 studies (11, 20, 21, 23-27). Two studies used the 145 
Sickness Index Profile (SIP) and the EQ-5D as outcome measures (11, 20); one study used 146 
the full EQ-5D (11), and the other used the visual analogue scale (20). Various versions of 147 
the GO-QOL were used in 9 out of 15 articles (11, 18-22, 26, 30, 31). 148 
Quality assessment 149 
The results of the quality assessment (16) indicate that the quality of studies varied 150 
considerably (mean = 20/32; range 14/32 to 31/32), but overall was reasonable (see 151 
supplementary file for additional details).  The most common issues relating to quality were 152 
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omission of details about recruitment (such as exclusion criteria, sources of recruitment, or 153 
participant characteristics), the use of incorrect statistical analysis or lack of such analysis, 154 
and lack of either the reporting of statistical power, or inadequate recruitment to reach 155 
statistical power.   In addition, the descriptions of treatment and its administration were 156 
often inadequate.  157 
Methimazole  158 
Abraham-Nordling et al. (24) found no significant difference, at any point between 159 
baseline and 4 years after treatment, in the physical or mental health-related quality of life 160 
between patients who received RAI and those that received methimazole.  Both groups did, 161 
however, experience a significant improvement in quality of life after treatment and from 3 162 
to 48 months after treatment the quality of life scores for physical health were equal to 163 
those of a Swedish general population reference group.  Notably however, it took 12 164 
months for mental health subscale scores to reach the same average for the reference 165 
population. This study also compared patients with GD with and withoutTED, and found that 166 
patients with TED at 2 years after methimazole treatment had significantly worse physical 167 
health-related quality of life as compared to  patients without eye disease.  At one year 168 
follow up, the authoƌs fouŶd ͞Ŷo Đleaƌ ĐoƌƌelatioŶ͟ ;p.ϲϱϱͿ ďetǁeeŶ oďjeĐtiǀe eǇe sĐoƌes 169 
and physical health or mental health subscale scores, however correlation coefficients have 170 
not been provided. Elberling et al. (27) found that, after a year of methimazole treatment, 171 
patients with GD (both those with and those without TED) had significantly lower mental 172 
and physical quality of life as compared to a healthy control group from the general 173 
population; these authors did not examine the differences between patients with GD with 174 
and without TED.  175 
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Orbital radiotherapy  176 
Using the GO-QOL, Prummel et al. (20) showed that patients at a year after orbital 177 
radiotherapy had similar quality of life scores to those receiving placebo radiotherapy, 178 
although this comparison was descriptive only.  Terwee et al. (11) did not find a significant 179 
improvement in the visual functioning subscale of GO-QOL at 6 months after radiotherapy 180 
(p=0.05).  Compared to orbital decompression, eye muscle surgery, eyelid lengthening or 181 
blepharoplasty, orbital radiotherapy led to the least improvement in appearance-related 182 
quality of life (11). Low correlation coefficients were found between changes in GO-QOL 183 
subscale scores and changes in clinical characteristics in this study. For the GO-QOL visual 184 
function subscale these include r = 0.27 for visual acuity and r = 0.27 for diplopia, and for the 185 
GO-QOL psychosocial function subscale these were r = 0.04 for lid aperture, r = 0.25 for 186 
proptosis and r = 0.28 for soft tissue involvement (11). In a cross-sectional study looking at 187 
long-term quality of life outcomes (up to 11 years) Terwee et al. (26) compared SF-36
TM
 188 
scores for patients that had received radiotherapy, steroids (or both treatments) with the 189 
scores for patients that completed the SF-36
TM
 before the start of radiotherapy or orbital 190 
surgery: they found that the treated group experienced significantly better quality of life 191 
than those newly diagnosed, except on the physical functioning and general health 192 
perceptions subscales. The treated group also reported significantly better quality of life on 193 
the GO-QOL appearance and visual functioning subscales. Notably these findings are for 194 
͞GO patieŶts afteƌ tƌeatŵeŶt͟ and are not reported by treatment type. The radiotherapy 195 
group experienced worse functional quality of life than the steroid treated group, but 196 
scored better on the GO-QOL appearance subscale: no analysis of statistical significance was 197 
reported for this finding however.  198 
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Systemic corticosteroids 199 
Using the SF-ϯϲ™, Kahaly et al. (23) reported a significant improvement in physical 200 
and mental health-related quality of life after IV methylprednisolone, but no significant 201 
changes after oral methylprednisolone.  Bartalena et al. (22) found that after 12 weeks of 202 
medium or high-dose IV methylprednisolone, there was a significant improvement in the 203 
GO-QOL visual function subscale and a significant improvement in appearance-related 204 
quality of life for those on low dose therapy.  Likewise, Aktaran et al. (30) found that, after 3 205 
months, 85% of the IV steroid group experienced significant improvements in vision-related 206 
quality of life and 81% had an improvement in the appearance subscale.  In a group 207 
receiving oral steroids, 76% showed improvement in visual function subscale scores and 208 
78% showed improvement in appearance subscale scores.  IV treatment led to significantly 209 
more improvements in quality of life scores than oral therapy.  210 
Of the participants in the study by Terwee et al. (26), 32% received prednisone, 211 
although it is unclear if this was oral or intravenous treatment.  As compared to those 212 
receiving radiotherapy, participants who received prednisone had a better overall quality of 213 
life, with the exception of the appearance subscale of GO-QOL and the SF-36™ vitality score. 214 
Kashkouli et al. (28, 29) studied the effects of corticosteroids on quality of life, but the 215 
method of administration is unclear in both studies. In 2009 the authors reported the 216 
change in mean scores from baseline to 6 months after treatment and suggest significant 217 
improvement in both GO-QOL subscale scores.  In the later study, both GO-QOL visual 218 
function and appearance subscales significantly improved after steroids, this contrasting 219 
with orbital decompression whereby only the appearance subscale scores improved.  In 220 
both the steroid and the decompression groups, over two-thirds achieved the minimum 221 
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clinically important difference in quality of life, with no significant difference between the 222 
two groups.  In both studies Kashkouli et al. failed to show any significant relationship 223 
between quality of life scores (before and after treatment) and clinical variables (including 224 
duration of disease, severity, or activity) (28, 29); however exact correlation coefficients 225 
have not been reported.  226 
Kulig et al. (25) reported that patients with TED had significantly reduced quality of 227 
life, assessed by the SF-ϯϲ™, as Đoŵpaƌed ǁith a healthǇ gƌoup of volunteers from the 228 
general population. They found that orbital radiotherapy, combined with 229 
methylprednisolone, improved quality of life in relation to physical functioning, bodily pain 230 
and vitality; it is unclear if these changes were statistically significant however.  The authors 231 
also found no correlation between quality of life and demographic or clinical variables; the 232 
authors have not reported the correlation coefficients found, however.  233 
Long-acting octreotide (octreotide-LAR)  234 
Dickinson et al. (18) reported a significant improvement in visual-related quality of 235 
life from pre-treatment to 16 weeks after administration of octreotide, and a significant 236 
improvement in appearance-related quality of life at 32 and 54 week follow-up, however 237 
significance levels were not reported.  Wémeau et al. (21) used both the SF-36™ and GO-238 
QOL, but merely report no significant changes in either quality of life score after treatment; 239 
exact data is not presented.  240 
Pentoxifylline and selenium  241 
Marcocci et al. (19) found no significant difference between the placebo and 242 
pentoxifylline on any of the GO-QOL subscales at 6 and 12 months after treatment.  A 243 
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significantly greater proportion of patients in the selenium group did exhibit an 244 
improvement in quality of life at 6 months, compared with those receiving a placebo (19). 245 
An improvement of 6 or more points on the appearance subscale was reported in 84% of 246 
those taking selenium, 72% on the visual function subscale and 81% in overall scores. 247 
Selenium led to a significant reduction in deterioration of quality of (as compared with those 248 
given placebo). Selenium had a beneficial effect on quality of life that continued up to 6 249 
months after treatment finished, both over time and when compared to the placebo group. 250 
However, the authors appear not to have analyzed the differences in quality of life 251 
improvements between the pentoxifylline and selenium groups. 252 
Surgery 253 
The EUGOGO consortium (31) investigated the impact of 18 different approaches to 254 
orbital decompression on quality of life using the GO-QOL. They observed improvements in 255 
the appearance subscale scores of between 17.4 and 39.9 points in all treatments, except 256 
for the translid and endoscopic approaches to decompression, in which the change was no 257 
more than 1.8 points.  Although no significance testing was performed, improvements 258 
appear to be substantial for a number of approaches, with many changes in scores reaching 259 
a minimal clinically important difference (MCID) for the GO-QOL (see Table 2).  Although the 260 
coronal approach led to the biggest improvement in appearance related quality of life, this 261 
approach caused the most frequent and serious complications.  262 
Terwee et al. (11) reported a significant improvement in the GO-QOL visual function 263 
subscale where orbital decompression was performed for sight loss, and an improvement in 264 
the appearance subscale when decompression was performed for disfiguring proptosis. The 265 
authors have highlighted that improvement on the GO-QOL can be seen in either the visual 266 
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function subscale, or appearance subscale, or both, depending on the type of treatment 267 
(11). For example the effect size for decompression for sight loss in the GO-QOL visual 268 
function subscale is 0.9 and the effect size for decompression for appearance in the GO-QOL 269 
appearance subscale is 0.45; for the SF-36™ physical and mental health subscales these are 270 
0.15 and 0.13, respectively.  Eyelid lengthening resulted in a lower mean change in 271 
appearance-related quality of life compared to the other treatments, although this was not 272 
significant. Blepharoplasty (which included 8 patients who had eyelid lengthening at the 273 
same surgery) led to significant improvements in the appearance subscale, these 274 
improvements being comparable to those after orbital decompression.   275 
 276 
Summary 277 
This is the first systematic review to evaluate the impact of treatment including 278 
drugs, radiotherapy and surgery for patients with TED.  In summary, radiotherapy was found 279 
to improve vision-related quality of life, but had the least improvement in appearance-280 
related quality of life compared to surgery. Intravenous methylprednisolone led to better 281 
quality of life outcomes than oral methylprednisolone and, even at low doses; the former 282 
improved appearance-related quality of life.  These studies also reported fewer adverse 283 
effects for IV corticosteroids as compared to oral, thereby making IV steroids a more 284 
favorable treatment both clinically and psychologically.  Long-term benefits in quality of life 285 
were found for octreotide-LAR, methimazole and selenium at up to 4 years after treatment. 286 
Eyelid lengthening and blepharoplasty were both found to improve appearance-related 287 
quality of life, although these findings need to be considered in light of the poor quality of 288 
studies.  Orbital decompression was found to have a larger effect on vision-related quality of 289 
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life when it was performed for failing vision, and a larger effect on appearance-related 290 
quality of life when surgery was performed for esthetic improvement.  291 
The reporting of participant characteristics varied greatly between studies, with 292 
many studies failing to report disease severity (27) or previous treatments (27, 28).  The 293 
severity of TED and prior treatment are important clinical factors that might contribute to a 294 
patieŶt͛s psychosocial adjustment and their subsequent quality of life.  The reporting of 295 
smoking status also varied, with only 6 of 15 studies reporting this data.  Smoking is an 296 
important factor in the onset and severity of TED, and the response of TED to treatment, 297 
and therefore smoking status might affect both the clinical and psychological quality of life 298 
outcomes; a recent systematic review provides some evidence for this contention (31).  The 299 
inclusion of a ͞no treatment͟ control group varied between RCTs, although this is not 300 
always possible in health research. Where particularly important confounding variables have 301 
not been accounted for – such as whether patients smoked, or if they were taking 302 
treatments additional to that under investigation – this could potentially affect the results of 303 
these studies.  Limitations of some of these studies make it impossible to give definite 304 
recommendations about the most effective treatments for improving quality of life.  305 
Furthermore not all of the studies reviewed included the TED-specific GO-QOL as a measure 306 
of quality of life in the population. Generic HRQL measures, such as the SF-36™, include 307 
items that are often too broad to capture the specific experiences of patients with TED, 308 
unlike the GO-QOL which is able to detect clinically important changes in scores from 309 
baseline to post-treatment follow-up (11). The GO-QOL has previously been recommended 310 
as a primary outcome measure in RCTs (33) and the present authors would like to 311 
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emphasize the importance of assessing the impact of treatments on the quality of life of 312 
patients.  313 
It is worth noting the limited number of studies that have examined quality of life 314 
after treatment, particularly in relation to orbital decompression: given how costly and 315 
physically invasive such procedures are, this is somewhat surprising. Despite the GO-QOL 316 
being recommended as an independent primary outcome measure in TED clinical trials (32), 317 
very few of the reviewed studies included this measure.   318 
The authors acknowledge that the exclusion of 33 foreign language articles could be 319 
a limitation of this review as one of these studies measured quality of life pre- and post-320 
orbital radiotherapy using the GO-QOL (34) and may have been eligible to include in the 321 
present findings.   322 
 323 
Conclusions 324 
The present review has brought together the results of a range of recommended 325 
treatments for TED on quality of life. It appears that whilst major treatments such as surgery 326 
do improve quality of life, other non-invasive treatments, such as IV steroids can have a 327 
similar impact and lead to long-term benefits. There remain few studies that have 328 
investigated how invasive surgical procedures such as orbital decompression impact on the 329 
quality of life of patients over the longer term.  330 
This review has also shown that the relationship between clinical and psychosocial 331 
outcomes remains unclear. There are a number of previous studies that suggest that a 332 
relationship does exist, for example Yeatts (35) found a correlation between quality of life 333 
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and the objective severity of TED characteristics such as diplopia and dry eye symptoms. 334 
However, the tool used to measure quality of life in this population; the Graves 335 
Ophthalmopathy Quality of Life Scale (GO-QLS), had been developed by choosing the items 336 
that correlated highly with clinical severity so this finding would be expected (35). Park et al. 337 
(2) found that poorer quality of life was associated with more severe disease; however the 338 
authors conclude that their research might have been overrepresented by severe cases. 339 
Interestingly, Moss (36) has described a possible ͚U͛ shaped Đuƌǀe ǁheƌe at the extreme 340 
ends of severity, i.e. in the least and most severe cases, objective and subjective ratings 341 
would be likely to correlate. Choi, Lim, Lee, Lee et al. (37) provide some evidence for this 342 
relationship having found that GO-QOL visual and appearance scores were significantly 343 
negatively correlated with clinical characteristics including soft tissue involvement, 344 
proptosis, severity score (NOSPECS) and activity (CAS). It might be likely that psychological 345 
processes rather than objective clinical measurements can better explain quality of life 346 
variability in patients with visibly disfiguring conditions (10), with some previous research 347 
supporting this notion in TED (8, 9) . However, there remain few studies that have 348 
investigated this relationship specifically in TED and, with mixed findings to date, further 349 
research is needed.   350 
Definite conclusions about the best treatment options and the overall effects of 351 
some treatments on quality of life remains unclear; due to poor reporting of methodology 352 
and results.  However, with the growing recognition that quality of life outcomes are an 353 
essential component of the outcome set for clinical trials, more robust evidence for quality 354 
of life changes will become available. As the GO-QOL has been found to be highly sensitive 355 
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to detecting changes after treatment for TED (11), it is recommended for use as a primary 356 
outcome measure in clinical trials for TED (33).   357 
Clinicians need to be aware when planning rehabilitative treatments such as surgery 358 
that there is variability in the effects they have on quality of life. The GO-QOL is 359 
recommended for use in the routine assessment of TED in order to identify patients that 360 
might benefit from psychological support (33). Patients need to be fully informed that whilst 361 
the aim of treatment is to improve clinical symptoms, not all treatments will improve their 362 
quality of life.  363 
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Table 1. The main characteristics of the studies included in the review  
Authors Country Design Control 
group 
Sample 
population 
Sample size Exclusion criteria Treatment type & 
administration 
Follow-up 
periods 
Bartalena et al. 
(2012) 
The 
Netherlands, 
Belgium, 
France, Italy, 
Switzerland, 
and Greece 
RCT No Moderate to 
severe, active 
TED 
159 CAS less than 3/7, optic 
neuropathy, patients not 
recommended for GC 
therapy, pregnancy, no 
informed consent, 
increased liver enzymes 
by a factor of 2 or more 
above upper normal 
limits.  
Three different 
doses of IV GC: 
2.25g (low dose), 
4.98g (middle 
dose), 7.47g (high 
dose) 
6, 12 and 24 
weeks 
Dickinson et al. 
(2004) 
UK & 
Germany 
RCT Yes Moderately 
severe, active 
TED 
50 Patients with sight-
threatening disease 
(NOSPECS 5b, 5c, or 6) 
Octreotide-LAR (30 
mg by injection at 4 
week intervals); 
placebo (prepared 
in ampoules of 
same volume and 
appearance as 
octreotide-LAR). 
16, 32, 44, and 
56 weeks 
Kahaly et al. 
(2005) 
Germany RCT No Untreated, 
active, severe 
TED 
70 
Not reported 
Oral GC (cumulative 
dose of 4.0g after 
12 weeks); IV GC 
(cumulative dose of 
4.5g).  
12 weeks and 6 
months 
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Marcocci et al. 
(2011) 
Holland, 
Germany, 
Switzerland, 
Italy, Greece  
RCT Yes Mild TED 152 NOSPECS class 2c1, 
exophthalmos >22 mm, 
diplopia and/or ocular 
torticollis, mono-ocular 
duction in any direction of 
less than 20 degrees, optic 
neuropathy, pregnancy, 
drug and/or alcohol 
abuse, severe 
concomitant illness, 
inability to comply with 
the study protocol, no 
informed consent, current 
use of selenium- or PTX-
containing preparations. 
“eleŶiuŵ ;ϭϬϬ μg 
orally twice daily 
for 6 months); PTX 
(600 mg orally 
twice daily for 6 
months); placebo 
(tablets twice a day 
for 6 months that 
looked identical to 
selenium and PTX) 
12 weeks, 6 
months and 12 
months 
Prummel et al. 
(2004) 
Holland RCT Yes Mild TED 88 Severe periorbital 
swelling, proptosis > 25 
mm, moderate or severe 
motility disturbances, 
optic neuropathy, 
contraindications for 
radiotherapy (mostly 
diabetes), severe 
concomitant disease, no 
informed consent 
Orbital 
radiotherapy (2 Gy 
daily over 2 weeks); 
sham irradiation 
(patients 
underwent the 
same procedures 
and the sound of 
the accelerator was 
simulated) 
12 weeks, 6 
months & 12 
months 
Wémeau et al. 
(2005) 
France RCT Yes Mild, active TED 51 Any other eye problem, 
gallstones, a history of 
treatment with systemic 
corticosteroids, 
immunosuppressive 
drugs, radiotherapy, or 
chemotherapy. 
Octreotide-LAR 
(2ml treatments by 
IM injection); 
placebo (2 ml 
treatments by IM 
injection) 
4 week 
intervals 
throughout the 
16 week 
treatment 
period, and 
again 6 months 
after the 
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beginning of 
treatment 
Abraham-
Nordling et al. 
(2010) 
Sweden Prospective 
randomized 
trial 
Healthy (did 
not receive 
treatment so 
only 
compared at 
one time 
point) 
Gƌaǀes͛ 
hyperthyroidism 
313 GD 
patients. 41 
patients had 
TED on entry 
into treatment 
groups. 76 
patients 
developed TED 
during the 
study 
(diagnosed 
during post-
treatment 
assessments).  
Previous history of 
treatments with ATDs, 
Iodine 131, or thyroid 
surgery, severe TED               
requiring treatment with 
corticosteroids, incipient 
toxic crisis, large goiters, 
CHD, pregnancy, breast-
feeding or planned 
pregnancy 
Methimazole; 
radioiodine (one 
administration for 
an absorbed dose 
of 120Gy) 
12 weeks, 12, 
24 and 36 
months (48 
months if eye 
symptoms 
continued to 
develop/ 
deteriorate) 
Aktaran et al.  
(2007) 
Turkey Prospective, 
randomized, 
single-blind 
trial 
No Active, 
moderately 
severe TED 
52 Corneal involvement (e.g. 
exposure keratitis), 
patients not 
recommended for GC 
therapy, a history of 
treatment with GCs, 
surgery or radiotherapy. 
IV GC (cumulative 
dose of 4.5g); high 
dose Oral GC 
(cumulative dose  
of 4 g) 
12 weeks 
EUGOGO 
consortium 
(2009) 
11 European 
centres: 
Holland, Italy, 
Greece, UK, 
Germany, 
France, 
Prospective 
cohort 
No Inactive TED 
patients seeking 
surgery 
118 
Not reported 
OD (17 different 
approaches) 
12 weeks 
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Switzerland 
Terwee et al. 
(2001) 
Holland Prospective 
cohort 
No TED patients 164; 
radiotherapy 
(n=23), OD for 
sight loss 
(n=10), OD for 
exophthalmos 
(n=38), EMS 
(n=31), EL 
(n=43), and 
blepharoplasty 
(n=19). 
Not reported 
Orbital 
radiotherapy; OD; 
EMS; EL; 
blepharoplasty 
(dose and 
administration of 
each not reported) 
12 weeks after 
surgery, 6 
months after 
radiotherapy 
Terwee et al. 
(2002) 
Holland Cross 
sectional  
Healthy (did 
not receive 
treatment so 
only 
compared at 
one time 
point) 
TED patients 
currently 
receiving 
radiotherapy 
treatment 
163 
Not reported 
Orbital 
radiotherapy; oral 
GC (prednisone); a 
combination of 
both 
immunosuppressive 
treatments (dose 
and administration 
not reported) 
Duration of 
follow-up was 
calculated as 
the time 
between the 
first visit to the 
clinic and the 
follow-up visit 
for this study. 
Average 
follow-up was 
11.7 years 
Kashkouli et al. 
(2009) 
Iran Cross-
sectional 
No TED  61 Absence of clinical and 
biochemical euthyroid 
state, presence of other 
chronic disorders such as 
diabetes mellitus, 
incomplete follow-up, and 
incomplete 
͚CoƌtiĐosteƌoids͛ 
(dose and 
administration not 
reported) 
6 months 
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questionnaires (more than 
10% missing data). 
Kashkouli et al. 
(2011) 
Iran Cross-
sectional 
No TED  67 Absence of clinical and 
biochemical euthyroid 
state, presence of other 
chronic disorders such as 
diabetes mellitus, and 
incomplete follow-up 
͚“teƌoids͛ (dose, 
type and 
administration not 
reported); OD 
(specific type not 
reported) 
6 months 
Elberling et al. 
(2004) 
Denmark Before and 
after study 
Yes Gƌaǀes͛ 
thyrotoxicosis 
27 GD patients. 
9 patients with 
toǆiĐ Gƌaǀes͛ 
disease also 
had signs or 
symptoms of 
TED as 
classified by 
NOSPECS on 
entry into the 
study 
Unable to read Danish, 
prior thyroid disease or 
psychiatric disorders, 
neurologic disorders 
known to influence 
neuropsychiatric 
functions, and other co-
morbidities 
Methimazole (dose 
and administration 
not reported) 
1 year 
Kulig et al. 
(2009) 
Not stated - 
authors are in 
Poland & 
Denmark 
Before and 
after study 
Healthy (did 
not receive 
treatment so 
only 
compared at 
one time 
point) 
Progressive 
infiltrative TED 
29 Other autoimmunological 
disease, previous 
treatment with oral 
steroids, orbital 
irradiation only or cyclical 
administration of 
methylprednisolone only, 
patients whose treatment 
was ceased because of 
complications, cessation 
of oral treatment with 
prednisone, patieŶt͛s 
Combined IV GC 
and orbital 
radiotherapy (6 
cycles of IV 
methylpred. 
sodium succinate) 
6 weeks 
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refusal to be examined 
after completing the full 
therapy, relapsing form of 
TED 
Acronyms: CHD = coronary heart disease, EMS = eye muscle surgery, EL = eyelid lengthening, IV GC = Intravenous glucocorticoid steroids, Oral GC = oral glucocorticoid 
steroids, Octreotide-LAR = Long-acting repeatable octreotide, OD = orbital decompression, PTX = pentoxifylline, RAI = radioiodine 
 
 
 
 
Table 2. Scores representing the mean change from pre-treatment to post-treatment follow-up for each quality of life outcome measure  
Treatment Author N Length of 
follow up 
GO-QOL Visual 
Function†  
GO-QOL 
Psychosocial 
Function† 
SF-36 Mental 
Component 
Score† 
SF-36 Physical 
Component 
Score† 
EuroQol† 
Methimazole Abraham-Nordling et 
al. (2010)  
N.B Authors did not 
test for statistical 
significance 
 
 
145    48 months - - 21* 16* - 
  Elberling et al. (2004)  
    30 12 months - - 8.1* ** 8.6* ** - 
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RAI Abraham-Nordling et 
al. (2010) 
 
163 48 months - - 17* 14* - 
 Radiotherapy Terwee et al. (2001)  
23 6 months 8.1 (18.6)** 2 (17.9) - - - 
  Prummel et al. 
(2004) 
 
26 12 months 8.2 (15.8) 6.7 (17.2) - - 1.2 (14.5) 
 
Terwee et al. 
(2002)N.B authors 
combined treatment 
scores  
 
21 
Various Not Reported
 
Not Reported
 
Not Reported
 
Not Reported
 
Not Reported 
IV Methylpred. Bartalena et al. 
(2012) 
N.B HD group showed 
the biggest change in 
mean scores 
 
 
52    3 months 
12.8 (7.2; 18.3) 
**  9 (4.5; 13.5) **  - - - 
  Kahaly et al. (2005)  
35    3 months - - Ϭ.ϱΐ ** Ϭ.ϰΐ ** - 
 Aktaran et al. (2007)     25 
3 months Not Reported Not Reported - - - 
Oral 
Methylpred. 
Aktaran et al. (2007) 27 
3 months Not Reported Not Reported - - - 
  Terwee et al. (2002) 
N.B authors combined 
treatment scores 
 
52 Various Not Reported
 
Not Reported
 
Not Reported
 
Not Reported
 
Not Reported 
  Kahaly et al. (2005) 35 
6 months - - 0.3 ** 0.1 - 
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Other GCs Kashkouli et al. 
(2009) 
N.B authors combined 
treatment scores 
61 
6 months Not Reported
 
Not Reported
 
- - - 
  Kashkouli et al. 
(2011) 
61 
6 months 20.1 ** 24.4 ** -  -  -  
Radiotherapy & 
GCs combined 
Terwee et al. (2002) 
N.B authors combined 
treatment scores 
90 
Various Not Reported
 
Not Reported
 
Not Reported
 
Not Reported
 
Not Reported 
  Kulig et al. (2009) 
N.B authors combined 
treatment scores 
29 
6 weeks - - Not Reported
 
Not Reported
 
- 
Octreotide-LAR Dickinson et al. 
(2004) 
23 
     14 months Not Reported Not Reported - - - 
  Wémeau et al. 
(2005) 
26 
6 months Not Reported Not Reported Not Reported Not Reported - 
PTX Marcocci et al. 
(2011) 
N.B Authors did not 
test for statistical 
significance 
 
48 
12 months -0.64 -0.9 - - - 
Selenium Marcocci et al. 
(2011) 
N.B Authors did not 
test for statistical 
significance 
 
54 
12 months 11 (15.3) 12.6 (11.8) - - - 
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 OD (sight loss) Terwee et al. (2001)  
10 3 months 20.3 (19.5) ** 4 (9.3) - - - 
  Kashkouli et al. 
(2011) 
 
6 6 months 34.6 36 ** - - - 
OD 
(exophthalmos) 
Terwee et al. (2001)  
38 3 months 3.2 (23.9) 11 (15.5) ** - - - 
 EUGOGO  et al. 
(2009) 
Swinging eyelid 
transcar (3 wall) 
 
26  
3 months 17.5 (20.8) 17.4 (24.5) - - - 
 Coronal (3 wall)  
14 3 months -1.7 (35.9) 39.9 (27) - - - 
 Translid endo (3 
wall) 
 
14 3 months -0.8 (9.5) 1.8 (9.5) - - - 
 Swinging eyelid 
transcar (2 wall) 
 
25 3 months 8.5 (20.9) 19.9 (22.9) - - - 
 Transcon transcar (2 
wall) 
 
18 3 months 7.9 (21.8) 9.7 (18.9) - - - 
 Endo (2 wall)  
10 3 months 2.3 (30) 34.5 (30.4) - - - 
 Translid (2 wall)  
11 3 months 13.6 (18.7) 22.1 (25.3) - - - 
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EMS Terwee et al. (2001)  
31 3 months 2.8 (25.4) 2.6 (22.2) - - - 
EL Terwee et al. (2001)  
43 3 months 3.7 (15) 4.2 (13.9) ** - - - 
Bleph. Terwee et al. (2001)  
19 3 months 0.2 (19.7) 10.2 (17.5) ** - - - 
** Findings were statistically significant   Minimal clinically important difference (MCID) achieved 
*Scores include GD and TED patients combined,  
ΐ Authors reported change in age- and gender-adjusted z scores for the SF-36 
Ώ Scale runs from 0 to 100 (higher scores indicate better QoL outcomes) 
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References 
 
 
  
Total identified from 
database searches             
n = 440 
Full copies retrieved 
and assessed for 
inclusion n = 188 
Excluded (n= 71) 
Title not relevant to GO = 65 
Paediatric population = 3 
Abstract only (not peer-reviewed 
published article) = 3 
Studies identified from 
searching key articles 
reference lists n = 2 
Publications meeting 
inclusion criteria n = 13 
Excluded (n= 175) 
Papers not printed in English = 33  
No validated QoL measures used = 42 
Reviews = 76 
Graves’ disease not TED = 11 
Baseline QoL only = 5 
Editorials and commentaries = 8 
g 
Studies included in 
the review n = 15 
Studies identified from 
email alerts n = 1 
Studies identified from 
contact with key 
authors n = 1 
Titles & abstracts 
screened n = 259 
Duplicates 
removed n = 183 
Figure 1. A flow diagram showing each stage of the study selection 
process 
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Supplementary File. Results of the quality assessment for the 15 studies included in the review 
Source 
A
b
ra
h
a
m
-
N
o
rd
li
n
g
 e
t 
a
l 
(2
0
1
0
) 
A
k
ta
ra
n
 e
t 
a
l 
(2
0
0
7
) 
B
a
rt
a
le
n
a
 e
t 
a
l 
(2
0
1
2
) 
D
ic
k
in
so
n
 e
t 
a
l 
(2
0
0
4
) 
E
lb
e
rl
in
g
 e
t 
a
l 
(2
0
0
4
) 
E
U
G
O
G
O
 e
t 
a
l 
(2
0
0
9
) 
K
a
h
a
ly
 e
t 
a
l 
(2
0
0
5
) 
K
a
sh
k
o
u
li
 e
t 
a
l 
(2
0
0
9
) 
K
a
sh
k
o
u
li
 e
t 
a
l 
(2
0
1
1
) 
K
u
li
g
 e
t 
a
l 
(2
0
0
9
) 
M
a
rc
o
cc
i 
e
t 
a
l 
(2
0
1
1
) 
P
ru
m
m
e
l 
e
t 
a
l 
(2
0
0
4
) 
T
e
rw
e
e
 e
t 
a
l 
(2
0
0
1
) 
T
e
rw
e
e
 e
t 
a
l 
 
(2
0
0
2
) 
W
é
m
e
a
u
 e
t 
a
l 
(2
0
0
5
) 
Aims and objectives 
clearly described 
               
Main outcomes clearly 
described in the 
Introduction or 
Methods section 
               
Patient characteristics 
clearly described (i.e. 
Inclusion and exclusion 
criteria are given) 
    -        -   
Interventions clearly 
described 
     -  - -    - -  
Distributions of 
principal confounders in 
each group clearly 
described 
    / -  -       - / -  
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Main findings clearly 
described 
               
Estimates of random 
variability in the data 
provided 
- -  -   - -       - 
Adverse events have 
been reported 
-       - - -  - - -  
Characteristics of 
patients lost to follow-
up have been described 
        -       
Actual probability 
values have been 
reported except where 
p< 0.001 
   - - -      -  -  
The subjects 
approached for the 
study were 
representative  
-               
The subjects who were 
prepared to participate 
were representative 
- -    - - - - -  - - - - 
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The staff, places, and 
facilities where the 
patients were treated 
were representative 
    -   - -  -    - 
Subjects were blinded -    - - - - - -   - -  
Those measuring the 
main outcomes were 
blinded 
-    - -  - - -   - -  
Any unplanned analyses 
were reported (if done) 
               
The analyses adjust for 
different lengths of 
follow-up of patients 
             -  
Statistical tests were 
appropriate 
-             - - 
Compliance with the 
interventions was 
reliable 
-  -  -      -  - - - 
Outcome measures 
were valid and reliable 
       - -       
 Page 32 of 41
Th
yr
oi
d
W
ha
t a
re
 th
e 
ps
yc
ho
so
ci
al
 o
ut
co
m
es
 o
f t
re
at
m
en
t f
or
 th
yr
oi
d 
ey
e 
di
se
as
e?
 A
 sy
ste
m
at
ic
 re
vi
ew
 (d
oi:
 10
.10
89
/th
y.2
01
4.0
03
7)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
33 
33 
 
Subjects in different 
intervention groups 
were recruited from the 
same population 
   -  -         - 
Subjects in different 
intervention groups 
were recruited over the 
same period of time 
   - -       - - -  
Subjects were 
randomised 
    - -  - - -   - -  
Randomisation was 
concealed from both 
patients and health care 
staff 
-    - - - - - -   - -  
Adequate adjustment 
for confounding in the 
analyses 
    - - -      -   
Losses of patients to 
follow-up were taken 
into account 
     -          
The study had sufficient 
power 
- -  - - - - - - - - - - - - 
Total score /32 18 25 31 23 16 15 22 17 17 21 25 23 14 14 21 
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Results of the quality assessment performed on the 15 studies included in the review 
 
                                                          
1 Bartley GB, Fatourechi V, Kadmas EF, Jacobson SJ, Ilstrup DM, Garrity JA, Gorman CA 1995 
The iŶĐideŶĐe of Gƌaǀes͛ ophthalŵopathǇ iŶ Olŵsted CouŶtǇ, MiŶŶesota. AŵeƌiĐaŶ JouƌŶal 
of Ophthalmology 120:511-7. 
  
2 Park JJ, Sullivan TJ, Mortimer RH, Wagenaar M, Perry-Keene DA 2004 Assessing quality of 
life in Australian patients with Gƌaǀes͛ ophthalŵopathǇ. Bƌitish JouƌŶal of OphthalŵologǇ 
88:75-78. 
 
3 Terwee CB, Gerding MN, Dekker FW, Prummel MF, van der Pol JP, Wiersinga WM 1999 
Test-retest reliability of the GO-QOL: a disease-specific quality of life questionnaire for 
patients with Gƌaǀes͛ ophthalŵopathǇ. JouƌŶal of CliŶiĐal EpideŵiologǇ ϱϮ;ϵͿ:ϴϳϱ-884. 
 
4 Jensen AL, Ingegerd H 2010 The impact of bodily change on social behaviour in patients 
with thyroid-associated ophthalmopathy. Scandinavian Journal of Caring Sciences. 25:341-
349 
  
5 Estcourt S, Vaidya B, Quinn A, Shepherd M 2008 The impact of thyroid eye disease upon 
patieŶts͛ ǁellďeiŶg: a Ƌualitatiǀe aŶalǇsis. CliŶiĐal EŶdoĐƌiŶologǇ ϲϴ:ϲϯϱ-639 
 
  Page 35 of 41 Page 36 of 417 89 4041
Th
yr
oi
d
W
ha
t a
re
 th
e 
ps
yc
ho
so
ci
al
 o
ut
co
m
es
 o
f t
re
at
m
en
t f
or
 th
yr
oi
d 
ey
e 
di
se
as
e?
 A
 sy
ste
m
at
ic
 re
vi
ew
 (d
oi:
 10
.10
89
/th
y.2
01
4.0
03
7)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
36 
36 
 
                                                                                                                                                                                    
6 Fichter N, Krentz H, Guthoff RF 2013 Functional and esthetic outcomes after bony lateral 
ǁall deĐoŵpƌessioŶ ǁith oƌďital ƌiŵ ƌeŵoǀal aŶd additioŶal fat ƌeseĐtioŶ iŶ Gƌaǀes͛ 
orbitopathy with regard to the configuration of the lateral canthal region. Orbit 32(4):239-
246. 
 
7 Boboridis KG, Bunce C 2011 Surgical orbital decompression for thyroid eye disease. The 
Cochrane Library 12 
 
8 Gerding MN, Terwee CB, Dekker FW, Koornneef L, Prummel MF, Wiersinga WM 1997 
Quality of life in patients with Graves' ophthalmopathy is markedly decreased: 
measurement by the medical outcomes study instrument. Thyroid 7:885-889. 
 
9 Terwee CB, Gerding MN, Dekker FW, Prummel MF, Wiersinga WM 1998 Development of a 
disease specific quality of life questionnaire for patients with Graves' ophthalmopathy: the 
GO-QOL. British Journal of Ophthalmology 82:773-779. 
 
10 Thompson A 2012 Researching Appearance: Models, Theories and Frameworks. In 
Rumsey N, Harcourt D (eds) The Oxford Handbook of The Psychology of Appearance, 1
st
 
edition. Oxford University Press, Oxford, UK, pp 91-109. 
 
11 Terwee CB, Dekker FW, Mourits MP, Gerding MN, Baldeschi L, Kalmann R, Prummel MF, 
Wiersinga WM ϮϬϬϭ IŶteƌpƌetatioŶ aŶd ǀaliditǇ of ĐhaŶges iŶ sĐoƌes oŶ the Gƌaǀes͛ 
ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments. Clinical 
Endocrinology 54:391-398.  
Th
yr
oi
d
W
ha
t a
re
 th
e 
ps
yc
ho
so
ci
al
 o
ut
co
m
es
 o
f t
re
at
m
en
t f
or
 th
yr
oi
d 
ey
e 
di
se
as
e?
 A
 sy
ste
m
at
ic
 re
vi
ew
 (d
oi:
 10
.10
89
/th
y.2
01
4.0
03
7)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
37 
37 
 
                                                                                                                                                                                    
 
12 Bradley EA, Gower EW, Bradley DJ, Meyer DR, Cahill KV, Custer PL, Holck DE, Woog JJ 
2008 Orbital radiation for Graves ophthalmopathy. a report by the American Academy of 
Ophthalmology. Ophthalmology 115:398-409. 
 
13 Rajendram R, Bunce C, Lee RWJ, Morley AMS 2012 Orbital radiotherapy for adult thyroid 
eye disease (Review). The Cochrane Library 7 
 
14 Viani GA, Boin AC, De Fendi LI, Fonseca EC, Stefano EJ, Silva De Paula, J 2012 Radiation 
theƌapǇ foƌ Gƌaǀes͛ ophthalŵopathǇ: a sǇsteŵatiĐ ƌeǀieǁ aŶd ŵeta-analysis of randomised 
controlled trials. Arquivos Brasileiros de Oftalmologia 75(5):324-332 
 
15 Downs SH, Black N 1998 The feasibility of creating a checklist for the assessment of the 
methodological quality both of randomised and non-randomised studies of health care 
interventions. Journal of Epidemiology and Community Health 52:377-384 
 
16 Wells K, Littell JH 2008 Study quality assessment in systematic reviews on intervention 
effects. Research on Social Work Practice 19:52-62 
 
17 Dickinson AJ, Vaidya B, Miller M, Coulthard A, Perros P, Baister E, Andrews CD, Hesse L, 
Heverhagen JT, Heufelder AE, Kendall-Taylor P 2004 Double-blind, placebo-controlled trial 
of octreotide Long-Acting Repeatable (LAR) in thyroid-associated ophthalmopathy. Journal 
of Clinical Endocrinology and Metabolism 89:5910-5915. 
 
Th
yr
oi
d
W
ha
t a
re
 th
e 
ps
yc
ho
so
ci
al
 o
ut
co
m
es
 o
f t
re
at
m
en
t f
or
 th
yr
oi
d 
ey
e 
di
se
as
e?
 A
 sy
ste
m
at
ic
 re
vi
ew
 (d
oi:
 10
.10
89
/th
y.2
01
4.0
03
7)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
38 
38 
 
                                                                                                                                                                                    
18 Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M, Altea MA, Nardi M, 
Pitz S, Boboridis K, Sivelli P, von Arx G, Mourits MP, Baldeschi L, Bencivelli W, Wiersinga W 
2011 Selenium and the course of mild Graves' orbitopathy. New England Journal of 
Medicine 364:1920-1931. 
 
19 Prummel MF, Terwee CB, Gerding MN, Baldeschi L, Mourits MP, Blank L, Dekker FW, 
Wiersinga W 2004 A randomized controlled trial of orbital radiotherapy versus sham 
irradiation in patients with mild Graves' ophthalmopathy. Journal of Clinical Endocrinology 
and Metabolism 89:15-20. 
 
20 Wémeau JL, Caron P, Beckers A, Rohmer V, Orgiazzi J, Borson-Chazot F, Nocaudie M, 
Perimenis P, Bisot-Locard S, Bourdeix I, Dejager S 2005 Octreotide (long-acting release 
foƌŵulatioŶͿ tƌeatŵeŶt iŶ patieŶts ǁith Gƌaǀes͛ oƌďitopathǇ: ĐliŶiĐal ƌesults of a fouƌ-month, 
randomized, placebo-controlled, double-blind study. Journal of Clinical Endocrinology & 
Metabolism 90(2):841-848 
 
21 Bartalena L, Krassas GE, Wiersinga W, Marcocci C, Salvi M, Daumerie C, Bournaud C, Stahl 
M, Sassi L, Veronesi G, Azzolini C, Boboridis KG, Mourits MP, Soeters MR, Baldeschi L, Nardi 
M, Curro N, Boschi A, Bernard M, von Arx, G 2012 Efficacy and safety of three different 
cumulative doses on intravenous methylprednisolone for moderate to severe and active 
Gƌaǀes͛ oƌďitopathǇ. JouƌŶal of CliŶiĐal EŶdoĐƌiŶology & Metabolism 97(12):4454-4463 
 
Th
yr
oi
d
W
ha
t a
re
 th
e 
ps
yc
ho
so
ci
al
 o
ut
co
m
es
 o
f t
re
at
m
en
t f
or
 th
yr
oi
d 
ey
e 
di
se
as
e?
 A
 sy
ste
m
at
ic
 re
vi
ew
 (d
oi:
 10
.10
89
/th
y.2
01
4.0
03
7)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
39 
39 
 
                                                                                                                                                                                    
22 Kahaly GJ, Pitz S, Hommel G, Dittmar M 2005 Randomized, single blind trial of 
intravenous versus oral steroid monotherapy in graves' orbitopathy. Journal of Clinical 
Endocrinology and Metabolism 90:5234-5240. 
 
23 Abraham-Nordling M, Wallin G, Traisk F, Berg G, Calissendorff J, Hallengren B, Hedner P, 
Lantz M, Nystrom E, Asman P, Lundell G, Torring O, The Thyroid Study Group of TT 96 2010 
Thyroid-associated ophthalmopathy; quality of life follow-up of patients randomized to 
treatment with antithyroid drugs or radioiodine. European Journal of Endocrinology 
163:651-657. 
 
24 Kulig G, Andrysiak-Mamos E, Sowinska-Przepiera E, Kulig J, Karakiewicz B, Brodowski J, 
Robaczyk M, Homa K, Letkiewicz M, Syrenicz A 2009 Quality of life assessment in patients 
with Graves' disease and progressive infiltrative ophthalmopathy during combined 
treatment with methylprednisolone and orbital radiotherapy. Endokrynologia Polska 60: 
158-165. 
 
25 Terwee C, Wakelkamp I, Tan S, Dekker F, Prummel MF, Wiersinga W 2002 Long-term 
effects of Graves' ophthalmopathy on health-related quality of life. European Journal of 
Endocrinology 146:751-757. 
 
26 Elberling TV, Rasmussen AK, Feldt-Rasmussen U, Hording M, Perrild H, Waldemar G 2004 
Impaired health-related quality of life in Graves' disease. A prospective study. European 
Journal of Endocrinology 151:549-555. 
 
Th
yr
oi
d
W
ha
t a
re
 th
e 
ps
yc
ho
so
ci
al
 o
ut
co
m
es
 o
f t
re
at
m
en
t f
or
 th
yr
oi
d 
ey
e 
di
se
as
e?
 A
 sy
ste
m
at
ic
 re
vi
ew
 (d
oi:
 10
.10
89
/th
y.2
01
4.0
03
7)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
40 
40 
 
                                                                                                                                                                                    
27 Kashkouli, M. B., Pakdel, F., Astaraki, A., Hashemi, M., Honarbakhsh, Y., Mirarmandehi, B. 
& Jam, S. (2009). Quality of life in patients with thyroid eye disease. Journal of Ophthalmic 
and Vision Research, 4, 164-168.  
 
28 Kashkouli MB, Heidari I, Pakdel F, Jam S, Honarbakhsh Y, Mirarmandehi B 2011 Change in 
quality of life after medical and surgical treatment of graves ophthalmopathy. Middle East 
African Journal of Ophthalmology 18:42-47. 
 
29 Aktaran S, Akarsu E, Erbagci I, Araz M, Okumus S, Kartal M 2007 Comparison of 
intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients 
ǁith Gƌaǀes͛ ophthalŵopathǇ. International Journal of Clinical Practice 61:45-51. 
 
30 EuƌopeaŶ Gƌoup oŶ Gƌaǀes͛ Orbitopathy (EUGOGO), Mourits MP, Bijl H, Altea MA, 
Baldeschi L, Boboridis K, Curro N, Dickinson AJ, Eckstein A, Freidel M, Guastella C, Kahaly GJ, 
Kalmann R, Krassas GE, Lane CM, Lareida J, Marcocci C, Marino M, Nardi M, Mohr Ch, Neoh 
C, Pinchera A, Orgiazzi J, Pitz S, Saeed P, Salvi M, Sellari-Franceschini S, Stahl M, von Arx G, 
Wiersinga W 2009 Outcome of orbital decompression for disfiguring proptosis in patients 
ǁith Gƌaǀes͛ oƌďitopathǇ using various surgical procedures. The British journal of 
ophthalmology 93:1518-1523. 
 
31 Thornton J, Kelly SP, Harrison RA, Edwards R 2007 Cigarette smoking and thyroid eye 
disease: a systematic review. Eye 21:1135-1145. 
 
Th
yr
oi
d
W
ha
t a
re
 th
e 
ps
yc
ho
so
ci
al
 o
ut
co
m
es
 o
f t
re
at
m
en
t f
or
 th
yr
oi
d 
ey
e 
di
se
as
e?
 A
 sy
ste
m
at
ic
 re
vi
ew
 (d
oi:
 10
.10
89
/th
y.2
01
4.0
03
7)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
41 
41 
 
                                                                                                                                                                                    
32 WieƌsiŶga W ϮϬϭϮ QualitǇ of life iŶ Gƌaǀes͛ ophthalŵopathǇ. Best PƌaĐtiĐe & ‘eseaƌĐh 
Clinical Endocrinology & Metabolism 26:359-370. 
 
34 Nasr E, Khater S, Nehme-Nasr D, Azoury F, Jambart S 2010 Corticosteroids and 
ƌadiotheƌapǇ iŶ the tƌeatŵeŶt of Gƌaǀes͛ ophthaŵlopathǇ. The Lebanese Medical Journal 
58(2):86-90 
 
35 Yeatts R P ϮϬϬϱ QualitǇ of life iŶ patieŶts ǁith Gƌaǀes͛ ophthalŵopathǇ. Transactions of 
the American Ophthamological Society 103:368-411 
 
36 Moss T P 2005 The relationships between objective and subjective ratings of 
disfigurement severity, and psychological adjustment. Body Image 2:151-159 
 
37 Choi Y J, Lim H T, Lee S J, Lee S Y, Yoon J S 2012 AssessiŶg Gƌaǀes͛ ophthalŵopathǇ-
specific quality of life in Korean patients. Eye 26:544-551 
 
 
 
 
 
 
 
 
Th
yr
oi
d
W
ha
t a
re
 th
e 
ps
yc
ho
so
ci
al
 o
ut
co
m
es
 o
f t
re
at
m
en
t f
or
 th
yr
oi
d 
ey
e 
di
se
as
e?
 A
 sy
ste
m
at
ic
 re
vi
ew
 (d
oi:
 10
.10
89
/th
y.2
01
4.0
03
7)
Th
is 
ar
tic
le
 h
as
 b
ee
n 
pe
er
-re
vi
ew
ed
 a
nd
 a
cc
ep
te
d 
fo
r p
ub
lic
at
io
n,
 b
ut
 h
as
 y
et
 to
 u
nd
er
go
 c
op
ye
di
tin
g 
an
d 
pr
oo
f c
or
re
ct
io
n.
 T
he
 fi
na
l p
ub
lis
he
d 
ve
rs
io
n 
m
ay
 d
iff
er
 fr
om
 th
is 
pr
oo
f.
